Will noninvasive screening for fibrosis/steatosis open Pandora's box? Sharing the healthcare burden of state-of-the-art hepatology practice

Affiliations

¹ Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
² Department of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Editorial

Sarah Khorasani et al. Hepatology. 2023.

. 2023 Apr 1;77(4):1085-1087.

doi: 10.1097/HEP.0000000000000235. Epub 2023 Jan 3.

¹ Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
² Department of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

No abstract available

Comment on

CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population.
Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Samala N, Chalasani N. Vilar-Gomez E, et al. Hepatology. 2023 Apr 1;77(4):1241-1252. doi: 10.1097/HEP.0000000000000023. Epub 2023 Jan 3. Hepatology. 2023. PMID: 36626638

1. Saiman Y, Duarte-Rojo A, Rinella ME. Fatty liver disease: diagnosis and stratification. Annu Rev Med. 2022;73:529–544.
1. Russo MW, Fix OK, Koteish AA, Duggan K, Ditmyer M, Fuchs M, et al. Modeling the Hepatology Workforce in the United States: a predicted critical shortage. Hepatology. 2020;72:1444–1454.
1. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486–1501.
1. Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71:371–378.
1. Loomba R. Utility of FIB-4, MRE, MRI-PDFF AND FIBROSCAN to identify patients with at-risk F2-F3 NASH based on screening data from a 2000 patient biopsy confirmed cohort of resmetiron phase 3 clinical trial, MAESTRO-NASH. 2022. The Liver Meeting . November 7, 2022.